For well over a hundred years, industrialized nations have continued to export a wide range of manufactured goods and associated technologies to developing countries throughout the world. More than altruism, it was viewed as an immediate economic opportunity, but also … Continue reading →

Today, Cardium Therapeutics announced the EU approval of uniQure’s Glybera® (alipogene tiparvovec). This first gene therapy approval by a major health regulatory authority represents a significant milestone and validation for the gene therapy industry. Glybera® was developed to treat patients … Continue reading →

When the FDA recently announced that it is considering a faster approval process for developers of drugs for serious diseases, it was important news for companies like Cardium Therapeutics, a San Diego-based health sciences and regenerative medicine developer. Development of … Continue reading →

The recent acquisition by Cardium Therapeutics, a health sciences and regenerative medicine company, of To Go Brands, a private California-based nutraceutical company, is in line with Cardium’s strategy of accelerating the growth and development of their own MedPodium health supplements … Continue reading →

A recent article in Genetic Engineering & Biotechnology News, the world’s number one biotech publisher, carried a good report on Cardium Therapeutics and Generx, a Cardium product candidate. Generx is a DNA-based angiogenic growth factor therapeutic used to stimulate the … Continue reading →

Cardium Therapeutics, known for the acquisition and strategic development of tissue repair and therapy technologies, also has a dynamic in-house healthy lifestyle product platform called MedPodium. Designed as a portfolio of premium, science-based nutraceuticals, metabolics, and aesthetics for the promotion … Continue reading →

Cardium Therapeutics this morning announced that its MedPodium® business has acquired the assets, business, and product portfolio of privately held To Go Brands® to support the expansion of its health sciences nutraceutical brand platform. Following the introduction of its products … Continue reading →

Cardium Therapeutics’ Generx product candidate is a good example of the company’s strategy of acquiring and developing new and innovative bio-medical product opportunities addressing unmet medical needs on a worldwide basis. Generx (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth … Continue reading →

Today before the opening bell, Cardium Therapeutics announced that Chairman & CEO Christopher J. Reinhard will be presenting at the BioX Noble Financial Life Sciences Exposition being held at the University of Connecticut, Stamford Campus on September 24 – 25, … Continue reading →

Today before the opening bell, Cardium Therapeutics announced the formation of the new Excellagen Medical Advisory Board. Comprised of leading practitioners, clinicians, and researchers with diversified expertise in the field of advanced wound care, the Medical Advisory Board has been … Continue reading →